Projects & Grants

Internal Grant Competition DGC
START-UP grant

Use of Pentraxin 3 in differential diagnosis of aspergillus syndrome II.
Project IdSGS05/LF/2022
Main solverMgr. Radim Dobiáš, Ph.D.
Period1/2022 - 12/2022
ProviderSpecifický VŠ výzkum
AnotationThe most clinically important member of the genus Aspergillus is Aspergillus fumigatus. Due to the small size of the spores, it penetrates deep into the human respiratory system and can cause various types of clinical problems under certain conditions. From hypersensitivity pneumonia through Allergic Broncho-Pulmonary Aspergillosis to the most severe form, invasive aspergillosis. The wide potential of this opportunistic pathogen applies to both outpatients and critically ill patients, where their primary involvement of the respiratory system or immune system allows this ubiquitous fungal microorganism to interact with the human body. This can occur due to primary hypersensitivity, immunodeficiency due to oncological diseases and their therapy, due to severe respiratory infections (H1N1, COVID19, bacterial infections), long-term antibiotic treatment and massive corticotherapy. A variety of biomarkers is used in the diagnosis of the clinical units listed above. In accordance to the diagnostic requirement or differentiate these clinical units earlier, methods for detecting specific early human inflammatory biomarkers, including Pentraxin 3 (PTX3), have recently been added to classical techniques. The aim of this follow-up study is to expand the control group of patients to a cohort of pulmonary bacterial infections, which will be subjected to measurement of serum PTX3 levels and the results will be attached to the study data from the SGS01-2021 project. Detection of PTX3 concentrations will be performed on another 100 serum samples and will be evaluated observationally and retrospectively. The total number of analysed patient serum samples for the period 2015 - 2021 will be 500. By analysing the data in this study, we obtain results that should serve in the future to better distinguish between hypersensitivity pneumonia, allergic bronchopulmonary aspergillosis and invasive aspergillosis.